From the upcoming September edition of Repertoire Magazine.
August 20, 2020 – Designed to meet the evolving and critical needs of point-of-care (POC) testing, the BD Veritor Plus system enables you to streamline the testing experience. Be ready for flu season by testing with CLIA-waived Flu A+B, Group A Strep, and respiratory syncytial virus (RSV) assays along with the SARS-CoV-2 assay, which is FDA authorized for emergency use in the current public health emergency.
The BD Veritor Plus system is an easy-to-use portable testing device that provides fast, reliable, and traceable results in acute as well as nonacute settings for Flu A+B, Group A Strep, RSV assays, along with a SARSCoV-2 assay under FDA emergency use authorization.
Understanding the needs of modern POC testing, results are fast – delivered in 15 minutes for SARSCoV-2, <11 minutes for flu and RSV, and <6 minutes for Group A Strep. Contributing to the reliability, the system enhances sensitivity by using a proprietary and stable detection particle technology, which helps improve test performance.
Simple and easy to operate, Flu A+B, Group A Strep, and RSV assays have all received CLIA-waived status to allow novice and nonlab personnel to test confidently. BD Veritor™ Plus system users also have access to the BD eLearning Platform, which provides quick, efficient, and customized training for the BD Veritor™ Plus system.
Results are designed to be traceable with the use of an optional BD Veritor™ InfoScan module, which allows users to reliably customize quality control and result documentation (user ID, specimen ID, and test kit/lot). Traceable results may reduce risk of potential reporting errors by minimizing manual transcription, leveraging data storage/download and printing capabilities via USB. The BD Veritor™ Plus system is powered by BD Synapsys™ Informatics, helping to streamline the testing experience with an integrated workflow and on-demand insights to keep up with the new demands of POC testing.